Deborah Gelinas is a Neurology physician affiliated with IDEX Corporation. OpenAlex indexes 96 publications with 5,119 citations (h-index 38).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
804 Service Road
Room A117
East Lansing, MI 488237038
Telephone
517-706-0348Registry record last updated 22 Jun 2016.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
55.4%Benzothiazole36.9%Riluzole100%Part D<11 patientsGabapentinoids18.5%Gabapentin100%Part D<11 patientsMusculoskeletal
24.6%gamma-Aminobutyric Acid-ergic Agonist24.6%Baclofen100%Part D<11 patientsRespiratory
20%Anticholinergic20%Glycopyrrolate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Risk–Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis
Advances in Therapy
2024 - Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis
Journal of the Neurological Sciences
2024 - The humanistic burden of myasthenia gravis: A systematic literature review
Journal of the Neurological Sciences
2022
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”